Home » Keryx Gets SPA Agreement with FDA for Phase III Registration Program of Zerenex
Keryx Gets SPA Agreement with FDA for Phase III Registration Program of Zerenex
Keryx Biopharmaceuticals, Inc. announced Tuesday that
it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical
program for Zerenex (ferric citrate), its iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in
patients with end-stage renal disease.
Earth Times
Earth Times
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May